Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated
worsening of disability, which is assumed to be mainly associated with transient infiltration of …

In contrast to the multiple disease-modifying therapies that are available for relapsing–
remitting multiple sclerosis (MS), the therapeutic options for progressive MS (PMS) are …

Microglia are implicated in all stages of multiple sclerosis (MS). Microglia alterations are
detected by positron emission tomography in people living with MS prior to the formation of …

There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …

Disability accrual in multiple sclerosis may occur as relapse-associated worsening or
progression independent of relapse activity. The role of progression independent of relapse …

As extremely sensitive immune cells, microglia act as versatile watchdogs of the central
nervous system (CNS) that tightly control tissue homeostasis. Therefore, microglial activation …

Over the past decade, single-cell genomics technologies have allowed scalable profiling of
cell-type-specific features, which has substantially increased our ability to study cellular …

Despite therapeutic suppression of relapses, multiple sclerosis (MS) patients often
experience subtle deterioration, which extends beyond the definition of “progression …

The classification of multiple sclerosis (MS) has been established by Lublin in 1996 and
revised in 2013. The revision includes clinically isolated syndrome, relapsing-remitting …

Abstract Translocator Protein 18 kDa (TSPO), previously named Peripheral Benzodiazepine
Receptor, is a well-validated and widely used biomarker of neuroinflammation to assess …